Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01415427 · ClinicalTrials.gov registry record · Phase 3
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 3 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
NCT01415427 is a Phase 3 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 173 participants.
The verdict
NCT01415427, a Phase 3 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
Study Summary
This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
Interventions
- DRUG BMN 110 - Weekly
- DRUG BMN 110 - Every Other Week
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-06-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01415427
The ClinicalTrials.gov registry entry for NCT01415427 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMN 110 - Weekly is the first listed.
NCT01415427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01415427 about?
NCT01415427 is a clinical study titled "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)". This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
What is the current status of trial NCT01415427?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2011-07. Estimated completion is 2016-06-16.
What interventions are being tested in trial NCT01415427?
The interventions under investigation include: BMN 110 - Weekly (DRUG), BMN 110 - Every Other Week (DRUG).
Who is sponsoring clinical trial NCT01415427?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.